Astellas installs president at OSI
This article was originally published in Scrip
Executive Summary
Astellas has named Naoki Okamura as president of its wholly owned US subsidiary OSI Pharmaceuticals. Mr Okamura was formerly an executive in Astellas's licensing and alliances department. Around a month ago, the Japanese firm completed its $4 billion acquisition of OSI, whose CEO is Dr Colin Goddard. The move will give Astellas a greater presence in the oncology sector and the US market (scripintelligence.com, 17 May 2010).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.